2227490-52-8
2227490-52-8
Chemical Structure
Mezagitamab
Synonym(s): TAK-079
- CAS No.: 2227490-52-8
- Formula:N/A
- Molecular Weight:(143.7 kDa)
IUPAC Name: 3-bromo-4-(1,1-difluoroethyl)pyridine
SMILES: [Mezagitamab]
Biological Activity: Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mezagitamab | 99.76% | Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Abadier M, et al. Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM)[J]. Blood, 2020, 136: 9.
- [2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. [Content Brief]
- [3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. [Content Brief]
